PURPOSE: The effect of statin medication use on the risk of prostate cancer is unknown. MATERIALS AND METHODS: We examined data from a longitudinal, population based cohort of 2,447 men between 40 and 79 years old who were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634, 26%) completed biennial urological examinations that included serum prostate specific antigen measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. RESULTS: Of 634 statin users 38 (6%) were diagnosed with prostate cancer vs 186 (10%) of 1,813 nonstatin users. Statin use was associated with a decreased risk of undergoing prostate biopsy (HR 0.31; 95% CI 0.24, 0.40), receiving a prostate cancer diagnosis (HR 0.36; 95% CI 0.25, 0.53) and receiving a high grade (Gleason 7 or greater) prostate cancer diagnosis (HR 0.25; 95% CI 0.11, 0.58). Statin use was also associated with a nonsignificantly decreased risk of exceeding a prostate specific antigen threshold of 4.0 ng/ml (HR 0.63; 95% CI 0.35, 1.13). In addition, a longer duration of statin use was associated with a lower risk of these outcomes (all tests for trend p <0.05). CONCLUSIONS: Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PURPOSE: The effect of statin medication use on the risk of prostate cancer is unknown. MATERIALS AND METHODS: We examined data from a longitudinal, population based cohort of 2,447 men between 40 and 79 years old who were followed from 1990 to 2007. Information on statin use was self-reported and obtained by biennial questionnaires. A randomly selected subset of men (634, 26%) completed biennial urological examinations that included serum prostate specific antigen measurements. Information on prostate biopsy and prostate cancer was obtained through review of community medical records. RESULTS: Of 634 statin users 38 (6%) were diagnosed with prostate cancer vs 186 (10%) of 1,813 nonstatin users. Statin use was associated with a decreased risk of undergoing prostate biopsy (HR 0.31; 95% CI 0.24, 0.40), receiving a prostate cancer diagnosis (HR 0.36; 95% CI 0.25, 0.53) and receiving a high grade (Gleason 7 or greater) prostate cancer diagnosis (HR 0.25; 95% CI 0.11, 0.58). Statin use was also associated with a nonsignificantly decreased risk of exceeding a prostate specific antigen threshold of 4.0 ng/ml (HR 0.63; 95% CI 0.35, 1.13). In addition, a longer duration of statin use was associated with a lower risk of these outcomes (all tests for trend p <0.05). CONCLUSIONS: Statin use is associated with a decreased risk of prostate cancer diagnosis. This association may be explained by decreased detection or cancer prevention. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Rosebud O Roberts; Debra J Jacobson; Cynthia J Girman; Thomas Rhodes; George G Klee; Michael M Lieber; Steven J Jacobsen Journal: Am J Epidemiol Date: 2003-05-01 Impact factor: 4.897
Authors: Patrick W J C Serruys; Pim de Feyter; Carlos Macaya; Norbert Kokott; Jacques Puel; Matthias Vrolix; Angelo Branzi; Marcelo C Bertolami; Graham Jackson; Bradley Strauss; Bernhard Meier Journal: JAMA Date: 2002-06-26 Impact factor: 56.272
Authors: Theresa J Arciero; Steven J Jacobsen; Guy S Reeder; Robert L Frye; Susan A Weston; Jill M Killian; V éronique L Roger Vr Journal: Am J Med Date: 2004-08-15 Impact factor: 4.965
Authors: Véronique L Roger; Jill Killian; Mary Henkel; Susan A Weston; Tauqir Y Goraya; Barbara P Yawn; Thomas E Kottke; Robert L Frye; Steven J Jacobsen Journal: J Clin Epidemiol Date: 2002-06 Impact factor: 6.437
Authors: Maria I Van Rompay; Keith R Solomon; J Curtis Nickel; Gayatri Ranganathan; Philip W Kantoff; John B McKinlay Journal: Eur J Cancer Date: 2019-03-06 Impact factor: 9.162
Authors: Jay H Fowke; Saundra S Motley; Daniel A Barocas; Michael S Cookson; Raoul Concepcion; Susan Byerly; Joseph A Smith Journal: Cancer Causes Control Date: 2010-12-19 Impact factor: 2.506
Authors: Mahmoud A Alfaqih; Emma H Allott; Robert J Hamilton; Michael R Freeman; Stephen J Freedland Journal: Nat Rev Urol Date: 2016-10-25 Impact factor: 14.432
Authors: June M Chan; Stephanie Litwack-Harrison; Scott R Bauer; Nicholas A Daniels; Timothy J Wilt; Jackilen Shannon; Douglas C Bauer Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-08-09 Impact factor: 4.254
Authors: Shaneabbas Raza; Megan Meyer; Jared Schommer; Kimberly D P Hammer; Bin Guo; Othman Ghribi Journal: Med Oncol Date: 2016-01-05 Impact factor: 3.064